Pulmonary function assessment post-left ventricular assist device implantation

Pavol Sajgalik, Chul Ho Kim, John M. Stulak, Sudhir S. Kushwaha, Simon Maltais, David L. Joyce, Lyle D. Joyce, Bruce David Johnson, John A. Schirger

Research output: Contribution to journalArticle

Abstract

Aim: The lungs—and particularly the alveolar-capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results: We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and diffusing capacity of the lung for carbon monoxide (DLCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9) years; male sex, n = 33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237 days post-LVAD implantation, we observed significant DLCO decrease (−23%) since pre-implantation (P < 0.001). ΔDLCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: ΔDLCO to ΔPCWP (r = 0.50, P < 0.01) and ΔDLCO to ΔRAP (r = 0.39, P < 0.05). We observed other reductions in FEV1, FVC, and FEV1/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV1 changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV1/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that ΔDLCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28–0.98); P = 0.03]. Conclusions: Pulmonary function did not improve after LVAD implantation. The degree of DLCO deterioration is related to haemodynamic status post-LVAD implantation. The ΔDLCO within 6 months post-operative was associated with survival.

Original languageEnglish (US)
JournalESC heart failure
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Heart-Assist Devices
Lung
Vital Capacity
Forced Expiratory Volume
Heart Failure
Pulmonary Wedge Pressure
Atrial Pressure
Hemodynamics
Lung Volume Measurements
Respiratory Function Tests
Carbon Monoxide
Survival Analysis
Stroke Volume
Retrospective Studies
Confidence Intervals
Pressure

Keywords

  • Continuous flow pumps
  • D
  • Pulmonary circulation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sajgalik, P., Kim, C. H., Stulak, J. M., Kushwaha, S. S., Maltais, S., Joyce, D. L., ... Schirger, J. A. (Accepted/In press). Pulmonary function assessment post-left ventricular assist device implantation. ESC heart failure. https://doi.org/10.1002/ehf2.12348

Pulmonary function assessment post-left ventricular assist device implantation. / Sajgalik, Pavol; Kim, Chul Ho; Stulak, John M.; Kushwaha, Sudhir S.; Maltais, Simon; Joyce, David L.; Joyce, Lyle D.; Johnson, Bruce David; Schirger, John A.

In: ESC heart failure, 01.01.2018.

Research output: Contribution to journalArticle

Sajgalik, Pavol ; Kim, Chul Ho ; Stulak, John M. ; Kushwaha, Sudhir S. ; Maltais, Simon ; Joyce, David L. ; Joyce, Lyle D. ; Johnson, Bruce David ; Schirger, John A. / Pulmonary function assessment post-left ventricular assist device implantation. In: ESC heart failure. 2018.
@article{bbae8467b4724a899ecb6e6548868e07,
title = "Pulmonary function assessment post-left ventricular assist device implantation",
abstract = "Aim: The lungs—and particularly the alveolar-capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results: We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and diffusing capacity of the lung for carbon monoxide (DLCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9) years; male sex, n = 33, 75{\%}] received either the HeartMate II (Thoratec Corp.) pump (77{\%}) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21{\%} (13{\%}). At a median of 237 days post-LVAD implantation, we observed significant DLCO decrease (−23{\%}) since pre-implantation (P < 0.001). ΔDLCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: ΔDLCO to ΔPCWP (r = 0.50, P < 0.01) and ΔDLCO to ΔRAP (r = 0.39, P < 0.05). We observed other reductions in FEV1, FVC, and FEV1/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV1 changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV1/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that ΔDLCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95{\%} confidence interval), 0.60 (0.28–0.98); P = 0.03]. Conclusions: Pulmonary function did not improve after LVAD implantation. The degree of DLCO deterioration is related to haemodynamic status post-LVAD implantation. The ΔDLCO within 6 months post-operative was associated with survival.",
keywords = "Continuous flow pumps, D, Pulmonary circulation",
author = "Pavol Sajgalik and Kim, {Chul Ho} and Stulak, {John M.} and Kushwaha, {Sudhir S.} and Simon Maltais and Joyce, {David L.} and Joyce, {Lyle D.} and Johnson, {Bruce David} and Schirger, {John A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ehf2.12348",
language = "English (US)",
journal = "ESC heart failure",
issn = "2055-5822",
publisher = "The Heart Failure Association of the European Society of Cardiology",

}

TY - JOUR

T1 - Pulmonary function assessment post-left ventricular assist device implantation

AU - Sajgalik, Pavol

AU - Kim, Chul Ho

AU - Stulak, John M.

AU - Kushwaha, Sudhir S.

AU - Maltais, Simon

AU - Joyce, David L.

AU - Joyce, Lyle D.

AU - Johnson, Bruce David

AU - Schirger, John A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aim: The lungs—and particularly the alveolar-capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results: We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and diffusing capacity of the lung for carbon monoxide (DLCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9) years; male sex, n = 33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237 days post-LVAD implantation, we observed significant DLCO decrease (−23%) since pre-implantation (P < 0.001). ΔDLCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: ΔDLCO to ΔPCWP (r = 0.50, P < 0.01) and ΔDLCO to ΔRAP (r = 0.39, P < 0.05). We observed other reductions in FEV1, FVC, and FEV1/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV1 changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV1/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that ΔDLCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28–0.98); P = 0.03]. Conclusions: Pulmonary function did not improve after LVAD implantation. The degree of DLCO deterioration is related to haemodynamic status post-LVAD implantation. The ΔDLCO within 6 months post-operative was associated with survival.

AB - Aim: The lungs—and particularly the alveolar-capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results: We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and diffusing capacity of the lung for carbon monoxide (DLCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9) years; male sex, n = 33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237 days post-LVAD implantation, we observed significant DLCO decrease (−23%) since pre-implantation (P < 0.001). ΔDLCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: ΔDLCO to ΔPCWP (r = 0.50, P < 0.01) and ΔDLCO to ΔRAP (r = 0.39, P < 0.05). We observed other reductions in FEV1, FVC, and FEV1/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV1 changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV1/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that ΔDLCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28–0.98); P = 0.03]. Conclusions: Pulmonary function did not improve after LVAD implantation. The degree of DLCO deterioration is related to haemodynamic status post-LVAD implantation. The ΔDLCO within 6 months post-operative was associated with survival.

KW - Continuous flow pumps

KW - D

KW - Pulmonary circulation

UR - http://www.scopus.com/inward/record.url?scp=85054867357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054867357&partnerID=8YFLogxK

U2 - 10.1002/ehf2.12348

DO - 10.1002/ehf2.12348

M3 - Article

JO - ESC heart failure

JF - ESC heart failure

SN - 2055-5822

ER -